COMP <GO>
SARO vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
StandardAero Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: SARO 7
— TMO 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TMO
LAST: $23.38 (-1.72%) • MKT CAP: $7.87B
balance-sheet
2.43
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SARO VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SARO | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 14.80% | 41.00% | -26.20 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.70% | 9.30% | +1.40 | SARO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.9x | 30.4x | -15.50 | SARO | /valuation <GO> |
| Free Cash Flow Yield | 2.98% | 2.40% | +0.58 | SARO | /fcf-yield <GO> |
| Operating Margin | 9.10% | 17.40% | -8.30 | TMO | /operating-margins <GO> |
| Net Profit Margin | 7.10% | 15.10% | -8.00 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 15.80% | 3.90% | +11.90 | SARO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.43 | 4.50 | -2.07 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.70% | +0.70 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.4 | 59.1 | +4.22 | SARO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.94 | +0.21 | SARO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.4x | 36.3x | -20.90 | SARO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.87B | $262.22B | -$254.34B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SARO REV | TMO REV | SARO GROSS % | TMO GROSS % | SARO FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.06B | $44.56B | 14.8% | 44.0% | $234.3M | $6.29B |
| FY 2024 | $5.24B | $42.88B | 14.4% | 44.0% | -$26.6M | $7.27B |
| FY 2023 | $4.56B | $42.86B | 44.0% | 44.0% | -$137.5M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SARO // BETA 1.15
TMO // BETA 0.94